INS and type 2 diabetes mellitus: Pop-Busui et al. [39] showed a glycemic control therapy with insulin-sensitizing significantly reduced the incidence of DPN compared with insulin-providing therapy among patients with type 2 diabetes followed for up to 4 years during the study.